Mirikizumab-mrkz (Omvoh) — Intravenous Infusion (Notification) Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity and prior authorization requirements for intravenous mirikizumab (Omvoh) for adults with moderately to severely active Crohn's disease or ulcerative colitis for Blue Cross Blue Shield North Carolina members.
For Crohn's disease: removed required trial and failure of conventional therapy and replaced allowance for severely active disease with required demonstration of moderately to severely active disease by documented symptoms plus evidence of inflammation OR significant extent/upper GI involvement OR corticosteroid-dependence/refractory to oral corticosteroids.
For ulcerative colitis: removed required trial and failure of conventional therapy and replaced allowance for severely active disease with required demonstration of moderately to severely active disease by documented symptoms plus evidence of inflammation or high-risk disease OR corticosteroid-dependence/refractory to oral corticosteroids.
Allowed patients currently established on a biologic or systemic immunomodulator (not the requested agent) who have had positive clinical benefit to be eligible under criteria when other conditions are met.
Added HCPCS code J2267 and dosing / maximum unit references for IV induction dosing by indication (CD and UC).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.